Updated: Having obtained safety data, Novartis seeks licensure for Bexsero vaccine in the U.S.
Do-Hyeong MyeongNovartis — the manufacturer of Bexsero, the meningitis B vaccine used tovaccinate University students this spring—announced that it is currently filing an application for FDA review of its vaccine, in the hopes of obtaining licensure. The use of Bexsero at the University and at the University of California at Santa Barbara has given Novartis safety data from 14,000 people, almost twice the number — 8,000 — that helped Novartis gain approval for Bexsero in Australia, Canada and the European Union, FierceVaccines reported.